

May 7, 2019

Symbio Pharmaceuticals Limited
 Fuminori Yoshida
 Representative Director,
 President and Chief Executive Officer

**Monthly Exercise Status of the 46th Stock Acquisition Rights (with Exercise Price Revision Clauses)
 Issued by way of Third Party Allotment**

TOKYO, Japan, May 7, 2019- The monthly exercise status for March of 46th Stock Acquisition Rights issued and allotted to EVO FUND on April 25, 2018.

(1)	Name of stock acquisition rights	Symbio Pharmaceuticals Limited 46 th Stock Acquisition Rights
(2)	Number of shares delivered for the month	5,784,000 Shares
(3)	Number of stock acquisition rights exercised during the month and exercise ratio to the total number of stock acquisition rights issued	5,784,000 Units (Ratio to total 15,000,000 Units Issued : 38.6 %)
(4)	Number of unexercised stock acquisition rights at the end of the previous month	14,000,000 Units
(5)	Number of unexercised stock acquisition rights at the end of the month	8,216,000 Units

(6) Exercise Status for respective month

Exercise Date	Number of shares issued		Exercise Price (¥)	Number of stock acquisition rights exercised (Units)
	New Shares (Shares)	Treasury Shares Transferred (Shares)		
April 1 (Mon) to April 5 (Fri.)	—	—	189	—
April 8 (Mon)	1,000,000	—	174	1,000,000
April 9 (Tue)	-	—	174	-
April 10 (Wed)	500,000	—	174	500,000
April 11 (Thu)	1,000,000	—	174	1,000,000
April 12 (Fri)	1,350,000	—	174	1,350,000
April 15 (Mon) to April 16 (Tue)	-	—	179	—
April 17 (Wed)	1,000,000	—	179	1,000,000
April 18 (Thu)	934,000	—	179	934,000
April 19 (Fri)	-	—	179	—
April 22 (Mon) to April 26 (Fri)	-	—	189	—

※Number of issued shares at the end of the previous month : 83,398,924 shares [of which 75shares are treasury shares]

(7) Status concerning restriction on exercise (Status concerning compliance with exercise restrictions under Article 434 of the Listing Regulations)

① Total number of shares to be delivered upon the exercise of all series of stock acquisition rights	② Number of listed shares at the time of the payment for the issuance	③ Exercise ratio on exercise limit (①/②)
5,784,000 Shares	57,840,724 Shares	10.00%

For further details regarding this issuance, please refer to “Notice of the Issuance of the 45th through 47th Stock Acquisition Rights with Exercise Price Revision Clauses (Committed Issue Program) and Conclusion of an Unsecured Loan Facility Agreement” published on April 9, 2018.